Latest news with #INR100
Yahoo
30-05-2025
- Business
- Yahoo
Alkem Laboratories Ltd (BOM:539523) Q4 2025 Earnings Call Highlights: Strong Domestic Growth ...
Total Revenue from Operations (FY25): INR 129,645 million, a Y-o-Y growth of 2.3%. Q4 Revenue from Operations: INR 31,438 million, with growth of 7.1%. India Sales (Q4): INR 2,155 million, Y-o-Y growth of 8.1%. International Business Sales (Q4): INR 9,747 million, Y-o-Y growth of 7.2%. Net Profit (FY25): INR 21,655 million, Y-o-Y growth of 20.6%. Net Profit (Q4): INR 3,059 million, growth of 4.2%. EBITDA (FY25): INR 25,122 million, Y-o-Y increase of 11.9%. EBITDA Margin (FY25): Expanded from 17.7% in FY24 to 19.4%. R&D Expenses (FY25): INR 5 million, 4.3% of total revenue from operations. Free Expenses (Q4): INR 1,585 million, close to 5% of total revenue. Volume Growth (FY25): 2.1% versus IPM's volume growth of 1.2%. Cadence (End of March 31, 2025): INR 46.2 billion. Warning! GuruFocus has detected 3 Warning Sign with NDSN. Release Date: May 29, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Alkem Laboratories Ltd (BOM:539523) reported a healthy growth in its India business during Q4 FY25, with an 8.1% year-over-year increase in domestic sales. The company achieved an EBITDA margin expansion from 17.7% in FY24 to 19.4% in FY25, indicating improved profitability. Alkem Laboratories Ltd (BOM:539523) outperformed the Indian Pharmaceutical Market (IPM) in volume growth by 90 basis points, with a 2.1% increase compared to IPM's 1.2%. The company is seeing good traction in its international business, excluding the Americas, with several key markets contributing significantly to growth. Alkem Laboratories Ltd (BOM:539523) is making strategic investments in R&D and expanding its biosimilar plant, which is expected to become operational by Q2 FY26, potentially driving future revenue growth. The company faced challenges in the injectable segment, impacting overall performance in certain therapies. Gross margins for Q4 FY25 were lower compared to the previous year due to reduced production and higher expiry in some markets. Alkem Laboratories Ltd (BOM:539523) experienced a mid-single-digit growth in its trade generic business, which has become highly competitive. The US business is expected to see only mid-single-digit growth due to ongoing price erosion and market dynamics. The company anticipates operating losses of INR100 to INR125 crores from its new CDMO and Medtech businesses in FY26, which could impact overall profitability. Q: In India, some major segments like anti-infectives and cardiac showed growth lower than IPM growth. Can you elaborate on this and the outlook for India business growth next year? A: Dr. Vikas Gupta, CEO: Despite some challenges in Q4, our annual performance in key therapies like GI, antidiabetic, and neuro has outperformed the market. We faced challenges in the injectable segment, but our oral solids and liquids have shown strong growth. We expect continued strong performance in our India business, with an 8.1% growth in Q4, and are optimistic about future growth. Q: How should we look at margins for FY26? A: Dr. Vikas Gupta, CEO: We expect EBITDA margins to remain stable at around 19.5% for FY26. While we will gain operating leverage from growth, we are also investing in R&D and market expansions, which will keep margins stable. Q: Can you update us on the biosimilar plant investment and its timeline? A: Dr. Vikas Gupta, CEO: The biosimilar project is on track and expected to be operational by Q2 FY26. We have invested around INR500 crores, and the total CapEx will be about INR550 crores. We anticipate revenue generation within this year. Q: What is the outlook for the US business in terms of growth and product launches? A: Dr. Vikas Gupta, CEO: We expect mid-single-digit growth in the US business for FY26. We plan to launch five to six new products, although no major launches are expected. The market remains competitive with ongoing price erosion, but we are optimistic about growth opportunities. Q: What is the guidance for R&D expenditure for FY26? A: Dr. Vikas Gupta, CEO: We expect R&D expenses to be around 5% of total revenue. This includes filings in non-US markets and the US, with plans to file eight to nine products. The focus will be on complex oral solids and injectables. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Economic Times
14-05-2025
- Automotive
- Economic Times
Tata's EV business loses market share but drives INR100 crore profit in FY25
In a paradox that few would have predicted, Tata Passenger Electric Mobility (TPEM) has turned Ebitda (earnings before interest, taxes, depreciation and amortisation) positive for the first time in FY25 — even as its stranglehold over India's electric vehicle (EV) market weakened significantly. The company reported a profit before tax (PBT) and exceptional items of INR100 crore, reversing a loss of INR400 crore in FY24. The Ebitda turnaround was
Time of India
14-05-2025
- Automotive
- Time of India
Tata's EV business loses market share but drives INR100 crore profit in FY25
In a paradox that few would have predicted, Tata Passenger Electric Mobility (TPEM) has turned Ebitda (earnings before interest, taxes, depreciation and amortisation) positive for the first time in FY25 — even as its stranglehold over India's electric vehicle (EV) market weakened significantly. The company reported a profit before tax (PBT) and exceptional items of INR100 crore, reversing a loss of INR400 crore in FY24. The Ebitda turnaround was
Express Tribune
22-03-2025
- Entertainment
- Express Tribune
No Shahrukh or Aamir: Who tops India's highest-paid actor list?
Listen to article Bollywood has long dominated India's entertainment industry, thanks to its massive Hindi-speaking audience. However, in recent years, South Indian cinema has surged in popularity, captivating audiences with high-energy action sequences, gripping narratives, and larger-than-life performances. This shift has propelled South Indian actors into the spotlight, with many now commanding some of the highest fees in the country. According to a recent The Indian Express article, which analyzed the earnings and assets of India's top ten actors using data sourced from Forbes, Allu Arjun has emerged as the highest-earning actor in India. With a string of successful films in a short period, Allu Arjun has cemented his place at the top. The report reveals that he earns approximately INR300 crores (INR3 billion) per film, with his total assets valued at INR350 crores. In second place is Joseph Vijay, a prominent South Indian actor, who charges between INR130 to 275 crores per film. His assets are valued at an impressive INR474 crores. Bollywood's Shah Rukh Khan, often called the "King of Bollywood," ranks third. He earns between INR150 to 250 crores per film, with his assets estimated at a staggering INR6300 crores. Rajinikanth, the legendary South Indian star, takes the fourth spot, with earnings of around INR270 crores per film and assets worth INR430 crores. Aamir Khan follows in fifth place, earning between INR100 to 175 crores per film. His assets are valued at INR1862 crores. Prabhas, who became a global sensation after Baahubali, ranks sixth, with earnings between INR100 to 200 crores per film. His assets are estimated at INR241 crores. Ajith Kumar occupies the seventh spot, earning between INR105 to 165 crores per film. His assets are valued at INR196 crores. In eighth place is Salman Khan, with earnings ranging between INR100 to 150 crores per film, and assets worth whopping INR2900 crores. Kamal haasan ranks ninth, earning between INR10 to 15 crores , with assets valued at INR150 crores. Finally, Akshay Kumar rounds out the list at tenth, earning between INR60 to 145 crores per film, with assets estimated at nearly INR2500 crores.
